Latest News

Teva’s New Real-World Evidence Presented at the 2024 AAN Annual Meeting Confirms Effectiveness and Patien

Teva Confirms Efficacy and Safety of AJOVY® (fremanezumab) for the Prevention of Migraine With Results fr

Teva to Host Conference Call to Discuss First Quarter 2024 Financial Results at 8 a.m. ET on May 8, 2024

New Pharmacokinetic Modeling Data Presented by Teva Simulates Clinical Profiles of Schizophrenia Patients

Teva and mAbxience Announce Strategic Global Licensing Agreement for Oncology Biosimilar Candidate

Clinical Collaboration Agreement between Teva and Launch Therapeutics to Accelerate Development of Dual-A

Teva and Jiangsu Nhwa Forge Strategic Partnership to Promote Patient Access to AUSTEDO® in China

Alvotech and Teva Announce U.S. Approval of SIMLANDI® (adalimumab-ryvk) injection, the first interchangea

Teva Presents New Data Supporting Safety, Tolerability and Target Engagement of Anti-TL1A (TEV-‘574) Anti

Teva Reports Growth in Fourth Quarter and Full Year 2023

Teva Announces Intention to Divest API Business as Part of Pivot to Growth Strategy

Teva to Host Conference Call to Discuss Fourth Quarter and Full Year 2023 Financial Results and 2024 Fina